Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing

Boehringer IngelheimBoehringer Ingelheim and BioMed X announced today that they have established a new research team of outstanding scientists from around the world that will conduct research to identify novel approaches for the treatment of patients with psychiatric diseases. The members of this team had submitted the most promising solution approaches in a crowdsourcing competition.

According to the World Health Organization, mental illness - together with substance abuse disorders - remains the leading cause of disability worldwide. At least 450 million people suffer from mental health problems. The global economic burden of mental illness is larger than for cancer, cardiovascular disease or diabetes and continues to grow - with significant health, social and economic consequences. As currently available treatment options leave many patients unsatisfactorily treated, more effective medicines for mental diseases are urgently needed.

"We are excited about applying the innovative approach of crowdsourcing to harness the creativity of the scientific community and combine it with our internal research and development capabilities, to discover the next generation of medicines for patients with psychiatric diseases who currently have insufficient treatment options," said Corporate Senior Vice President Clive R. Wood, Head of Discovery Research of Boehringer Ingelheim. "Our scientists will work closely with the new team we are establishing with our partner BioMed X, thereby further supporting our ambition to be an innovation leader in psychiatric diseases."

Christian Tidona, founder and Managing Director of BioMed X explained: "With this new neuroscience research group our center is growing to over 60 top researchers from around the world. We are excited about our strong partnership with Boehringer Ingelheim which is driven by scientific excellence and mutual trust."

The interdisciplinary team will focus on the generation of novel therapeutic approaches for psychiatric diseases by developing a highly integrated brain microcircuit model which includes authentic neuronal and non-neuronal cells and supports functional readouts with sufficient robustness and throughput for drug discovery. Michał Ślęzak will head the research team that will be established in the BioMed X Innovation Center located on the campus of the University of Heidelberg, Germany. The new project follows on the successful establishment of a group to identify novel epigenetic drivers to find new approaches for treating COPD and underscores Boehringer Ingelheim's long term sustainable collaboration approach.

The new crowdsourcing initiative is just one example of the increasing focus Boehringer Ingelheim puts on partnering, constantly seeking new innovative collaboration models to adapt to the needs of its partners and maximize mutual benefit. The research team will be sponsored by Boehringer Ingelheim for two years with the option to extend the funding period up to a total of four years. Further details of the agreement are not disclosed.

About BioMed X Innovation Center
The BioMed X Innovation Center is an exciting new collaboration model at the interface between academia and industry. At the center, distinguished early career scientists recruited from all over the world are working jointly on novel pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, diagnostics and bioinformatics.

About Boehringer Ingelheim
Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative “Making More Health” while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.

In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...